Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
:NBY
Total Valuation
NovaBay Pharma has a market cap or net worth of $6.61M. The enterprise value is -$1.06M.
Market Cap$6.61M
Enterprise Value-$1.06M
Share Statistics
NovaBay Pharma has 6,010,749 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,010,749
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
NovaBay Pharma’s return on equity (ROE) is 55.99 and return on invested capital (ROIC) is -378.42%.
Return on Equity (ROE)55.99
Return on Assets (ROA)-2.11
Return on Invested Capital (ROIC)-378.42%
Return on Capital Employed (ROCE)-10.07
Revenue Per Employee752.38K
Profits Per Employee-554.62K
Employee Count13
Asset Turnover2.86
Inventory Turnover4.31
Valuation Ratios
The current PE Ratio of NovaBay Pharma is ―. NovaBay Pharma’s PEG ratio is 0.00288.
PE Ratio―
PS Ratio0.21
PB Ratio-15.82
Price to Fair Value-15.82
Price to FCF-0.39
Price to Operating Cash Flow-0.88
PEG Ratio0.00288
Income Statement
In the last 12 months, NovaBay Pharma had revenue of 9.78M and earned -7.22M in profits. Earnings per share was -2.53.
Revenue9.78M
Gross Profit6.48M
Operating Income-5.84M
Pretax Income-7.21M
Net Income-7.22M
EBITDA-5.92M
Earnings Per Share (EPS)-2.53
Cash Flow
In the last 12 months, operating cash flow was -6.97M and capital expenditures 0.00, giving a free cash flow of -6.97M billion.
Operating Cash Flow-6.97M
Free Cash Flow-6.97M
Free Cash Flow per Share-1.16
Dividends & Yields
NovaBay Pharma pays an annual dividend of $0.8, resulting in a dividend yield of ―
Dividend Per Share$0.8
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.04
52-Week Price Change129.79%
50-Day Moving Average1.26
200-Day Moving Average0.68
Relative Strength Index (RSI)45.77
Average Volume (3m)1.08M
Important Dates
NovaBay Pharma upcoming earnings date is Mar 26, 2026, After Close (Confirmed).
Last Earnings DateNov 7, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend DateSep 30, 2025
Financial Position
NovaBay Pharma as a current ratio of 0.68, with Debt / Equity ratio of 24.55%
Current Ratio0.68
Quick Ratio0.41
Debt to Market Cap0.28
Net Debt to EBITDA-0.21
Interest Coverage Ratio-6.46
Taxes
In the past 12 months, NovaBay Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
NovaBay Pharma EV to EBITDA ratio is -0.55, with an EV/FCF ratio of -0.63.
EV to Sales0.34
EV to EBITDA-0.55
EV to Free Cash Flow-0.63
EV to Operating Cash Flow-0.63
Balance Sheet
NovaBay Pharma has $2.31M in cash and marketable securities with $970.00K in debt, giving a net cash position of $1.34M billion.
Cash & Marketable Securities$2.31M
Total Debt$970.00K
Net Cash$1.34M
Net Cash Per Share$0.22
Tangible Book Value Per Share-$0.04
Margins
Gross margin is 63.20%, with operating margin of -59.70%, and net profit margin of -73.85%.
Gross Margin63.20%
Operating Margin-59.70%
Pretax Margin-73.71%
Net Profit Margin-73.85%
EBITDA Margin-60.58%
EBIT Margin-64.47%
Analyst Forecast
The average price target for NovaBay Pharma is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast-74.73%
EPS Growth Forecast95.81%